Verano Holdings (VRNO) Non-Current Assets (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Non-Current Assets of $29.0 million for Q1 2026, down 0.65% year-over-year from $29.2 million in Q1 2025, and down 2.63% quarter-over-quarter from $29.8 million in Q4 2025.
Verano Holdings (VRNO) Non-Current Assets (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Non-Current Assets for 6 consecutive years, with $29.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 0.65% year-over-year to $29.0 million; the TTM figure through Mar 2026 stood at $29.0 million (down 0.65% YoY), while the FY2025 annual figure was $29.8 million, up 12.23% from the prior year.
- Non-Current Assets slipped to $29.0 million in Q1 2026 per VRNO's latest filing, from $29.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $95.4 million in Q3 2022 and bottomed at $21.7 million in Q3 2023.
- Historically, Non-Current Assets has averaged $42.1 million across 5 years, with a median of $29.0 million in 2025.
- Annual changes were most pronounced in 2023 — Non-Current Assets sank 77.28% — and 2024, when it gained 15.95%.
- Verano Holdings' Non-Current Assets stood at $72.1 million in 2022, then tumbled by 60.37% to $28.6 million in 2023, then decreased by 7.05% to $26.6 million in 2024, then climbed by 12.23% to $29.8 million in 2025, then slipped by 2.63% to $29.0 million in 2026.
- Business Quant data shows VRNO's Non-Current Assets at $29.0 million in Q1 2026, $29.8 million in Q4 2025, and $28.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 2.96 Bn |
| 10 | Verano Holdings | 441.74 Mn | 356.55 Mn | 99.70 Mn | 28.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.11 Mn |
| Mar 31, 2026 | 29.02 Mn |
| Dec 31, 2025 | 29.80 Mn |
| Sep 30, 2025 | 28.22 Mn |
| Jun 30, 2025 | 28.98 Mn |
| Mar 31, 2025 | 29.21 Mn |
| Dec 31, 2024 | 26.56 Mn |
| Sep 30, 2024 | 25.13 Mn |
| Jun 30, 2024 | 26.27 Mn |
| Mar 31, 2024 | 26.73 Mn |
| Dec 31, 2023 | 28.57 Mn |
| Sep 30, 2023 | 21.67 Mn |
| Jun 30, 2023 | 81.82 Mn |
| Mar 31, 2023 | 82.67 Mn |
| Dec 31, 2022 | 72.08 Mn |
| Sep 30, 2022 | 95.36 Mn |
| Dec 31, 2021 | 207.91 Mn |